Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2016

01.04.2016 | Letter to the Editor

Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1

verfasst von: C. L. Gorter de Vries, S. C. Linn, D. Brandsma

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor, …
Literatur
1.
Zurück zum Zitat Ross J, Slodkowsaka E, Symmans W et al (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320–369CrossRefPubMed Ross J, Slodkowsaka E, Symmans W et al (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320–369CrossRefPubMed
2.
Zurück zum Zitat Verma S, Miles D, Gianni L et al for the EMILIA Study Group (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791 Verma S, Miles D, Gianni L et al for the EMILIA Study Group (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791
3.
Zurück zum Zitat Metro G, Foglietta J, Russillo M et al (2011) Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 22(3):625–630CrossRefPubMed Metro G, Foglietta J, Russillo M et al (2011) Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 22(3):625–630CrossRefPubMed
4.
Zurück zum Zitat Bartsch R, Berghoff A, Preusser M (2014) Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neurooncol 116:205–206CrossRefPubMed Bartsch R, Berghoff A, Preusser M (2014) Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neurooncol 116:205–206CrossRefPubMed
5.
6.
Zurück zum Zitat Gebhart G, Lamberts LE, Wimana Z et al (2015) Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial. Ann Oncol. doi:10.1093/annonc/mdv577 Gebhart G, Lamberts LE, Wimana Z et al (2015) Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial. Ann Oncol. doi:10.​1093/​annonc/​mdv577
Metadaten
Titel
Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1
verfasst von
C. L. Gorter de Vries
S. C. Linn
D. Brandsma
Publikationsdatum
01.04.2016
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2016
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-015-2045-1

Weitere Artikel der Ausgabe 2/2016

Journal of Neuro-Oncology 2/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.